# A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

> **NCT01969682** · PHASE1 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** ABT-199
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT01969682
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-04
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study will be conducted in healthy volunteer subjects.
- **Last updated:** 2014-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01969682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01969682, "A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01969682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*